Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-03T11:53:28.692Z Has data issue: false hasContentIssue false
  • English
  • Français

Association between brain-derived neurotrophic factor and symptoms of insomnia and depression in inflammatory bowel disease (IBD) patients

Published online by Cambridge University Press:  13 August 2021

M. Sochal ,
P. Bialasiewicz ,
A. Gabryelska ,
J. Fichna ,
R. Talar-Wojnarowska  and
E. Małecka-Panas
M. Sochal*
Affiliation:
Department Of Sleep Medicine And Metabolic Disorders, Medical University of Lodz, Poland, Lodz, Poland
P. Bialasiewicz
Affiliation:
Department Of Sleep Medicine And Metabolic Disorders, Medical University of Lodz, Poland, Lodz, Poland
A. Gabryelska
Affiliation:
Department Of Sleep Medicine And Metabolic Disorders, Medical University of Lodz, Poland, Lodz, Poland
J. Fichna
Affiliation:
Department Of Biochemistry, Medical University of Lodz, Lodz, Poland
R. Talar-Wojnarowska
Affiliation:
Department Of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland
E. Małecka-Panas
Affiliation:
Department Of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Brain-derived neurotrophic factor (BDNF) plays an important role in depression and sleep disorders. It influences the inflammatory process and may affect the interactions between psychological state and gastrointestinal symptoms.

Objectives

The study aimed to compare BDNF concentrations in the group of Crohn’s disease (CD), ulcerative colitis (UC) patients, and healthy control (HC), as well as to correlate it with the severity of depression and insomnia.

Methods

The study included 94 inflammatory bowel disease patients (IBD, 57 CD, and 37 UC) and 26 HC. Each participant completed the following questionnaires: Pittsburgh Sleep Quality Index (PSQI), Athens insomnia scale (AIS), and Beck Depression Inventory (BDI). BDNF protein concertation measurements were performed using ELISA. Funding: National Science Centre, Poland-2018/31/N/NZ5/03715.

Results

CD patients had a higher serum level of BDNF (22.5 ng/mL, IQR:17.5-28.5) than UC patients (19.1 ng/mL, IQR:12.3-24.6; p=0.045). CD group had higher BDNF concentrations than HC (17.5 ng/mL, IQR:13.2-23.8; p=0.010), but no such differences were found between UC and HC groups (p=0.544). A positive correlation was found between AIS and BDNF among IBD (r=0.22, p=0.035). Additionally, patients, who obtained high BDI scores (>7 points) had lower BDNF concentrations than others (p=0.004). The patients with long sleep latency (>10 min) achieved a higher BDNF level than others (p=0.038). However. BDNF level did not correlate with PSQI results.

Conclusions

BDNF serum level is increased in CD, but not in UC patients. Overall, the severity of insomnia symptoms correlates positively with BDNF levels. Future research should focus on the further explanation of those observations.

Keywords

BDNFInsomniapsychosomaticsinflammatory bowel disease
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S554
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.